Stress-inducible phosphoprotein 1 (STI1) acts as a neuroprotective factor in the ischemic brain and its levels are increased following ischemia. Previous work has suggested that some of these STI1 actions in a stroke model depend on the recruitment of bone marrow-derived stem cells to improve outcomes after ischemic insult. However, STI1 can directly increase neuroprotective signaling in neurons by engaging with the cellular prion protein (PrP C ) and activating a7 nicotinic acetylcholine receptors (a7nAChR). Given that a7nAChR activation has also been involved in neuroprotection in stroke, it is possible that STI1 can have direct actions on neurons to prevent deleterious consequences of ischemic insults. Here, we tested this hypothesis by exposing primary neuronal cultures to 1-h oxygen-glucose deprivation (OGD) and reperfusion and assessing signaling pathways activated by STI1/PrP C . Our results demonstrated that STI1 treatment significantly decreased apoptosis and cell death in mouse neurons submitted to OGD in a manner that was dependent on PrP C and a7nAChR, but also on the activin A receptor 1 (ALK2), which has emerged as a signaling partner of STI1. 
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Stress-inducible phosphoprotein I (STIP1, STI1) is a cochaperone for heat-shock protein 70 (Hsp70) and Hsp90 that has also extracellular functions, acting as a 'cytokine-like' molecule (Lackie et al. 2017) . As a co-chaperone, STI1 helps with the transfer of client proteins from Hsp70 to Hsp90 by binding onto both simultaneously via its tetratricopeptide repeat domains to maintain protein quality control (Lassle et al. 1997; Schmid et al. 2012) . Similarly to Hsp70, Hsp90 (Clayton et al. 2005; Lancaster and Febbraio 2005) and some of their co-chaperones, such as cyclophilin A (Suzuki et al. 2006) , STI1 is secreted by cells, including glia in the nervous system (Fonseca et al. 2012; Beraldo et al. 2013; Hajj et al. 2013 ). STI1 secretion is carried out, at least in part, by exosomes , and extracellular STI1 can signal to increase neuronal protection and differentiation (Zanata et al. 2002; Lopes et al. 2005; Caetano et al. 2008; Beraldo et al. 2010 Beraldo et al. , 2013 . Extracellular STI1 interacts with the prion protein (PrP C ) with high-affinity (K D~1 00 nM; Zanata et al. 2002; Ostapchenko et al. 2013; Maciejewski et al. 2016) , triggering calcium signaling in neurons that depends on a7 nicotinic acetylcholine receptors (a7nAChR; Beraldo et al. 2010; Ostapchenko et al. 2013) . STI1-induced calcium influx can activate protein kinase A protecting retinal and hippocampal neurons against staurosporine-induced programmed cell death (Zanata et al. 2002; Lopes et al. 2005; Beraldo et al. 2010) . In addition, STI1/PrP C engagement in primary neurons can induce differentiation through activation of the extracellular signal-regulated kinase 1 and 2, and protein synthesis by activation of phosphoinositide 3-kinase-Aktmediated mechanistic target of rapamycin (Lopes et al. 2005; Roffe et al. 2010) . STI1 is also secreted by a number of tumor cells (Wang et al. 2010 (Wang et al. , 2017b . In an ovarian tumor, secreted STI1 has been shown to signal via PrP C or via ALK2 receptors (Activin A receptor, type 1 or ACVR1; Tsai et al. 2012) . Secreted STI1, acting in an autocrine and paracrine fashion, can bind and activate ALK2 to induce cell proliferation via SMAD-regulated transcription of target genes (Tsai et al. 2012) . Both autocrine and paracrine actions of STI1 have been observed in tumors by activation of ALK2 and PrP C (Chen et al. 2017; Wang et al. 2017b) . PrP C , a glycosylphosphatidylinositol-anchored protein, seems to function as a main organizer of signal platforms at the cellular surface (Linden et al. 2008; Martins et al. 2010) . In ischemic conditions, PrP C expression is increased in both human and mouse tissues (McLennan et al. 2004) . Interestingly, PrP C -null mice show increased infarct volume following ischemia (Weise et al. 2006) . On the other hand, transgenic mice with increased PrP C expression present decreased injury and dysfunction when compared to control animals, an observation that was mirrored by adenovirusmediated over-expression of PrP C (Shyu et al. 2005; Weise et al. 2008 ). STI1 expression is also increased under ischemic conditions as a result of the direct binding of the hypoxia-inducible factor-1a onto the STI1 gene promoter (Lee et al. 2013) . STI1 has been shown to recruit bone marrow-derived stem cells into ischemic brains and promote their proliferation in a PrP C -dependent way, ultimately facilitating neurological recovery following stroke (Lee et al. 2013) . STI1 also directly prevents neuronal death in a PrP C -dependent manner in response to oxygen/glucose deprivation, which models ischemic conditions in cell culture (OGD; Beraldo et al. 2013) . Accordingly, decreased expression of STI in heterozygous knockout mice increases ischemic damage in the middle cerebral artery occlusion model of stroke .
Although increased STI1 levels improve the outcomes in models of stroke Lee et al. 2013) , the mechanism by which STI1 protects neurons against ischemic insults is poorly understood. Furthermore, whether a7nAChRs participate in this process remains unknown. Interestingly, a7nAChRs have been shown to protect brain tissue in different models of ischemic and hemorrhagic stroke (Krafft et al. 2013; Sun et al. 2013) , by modulating neuroinflammation (Han et al. 2014) , neurogenesis (Wang et al. 2017a) , and by activating neuroprotective signaling pathways (Dajas-Bailador et al. 2000; Kihara et al. 2001; Beraldo et al. 2010) . Hence, understanding whether STI1 can endogenously activate these and other signaling pathways in ischemic neurons is relevant for the future development of STI1-based compounds. Here, we show that STI1 can prevent ischemia-induced apoptosis and that the neuroprotection by STI1 is also dependent on a7nAChRs and ALK2 receptors. Interestingly, bone morphogenetic protein 4 (BMP4), an agonist of ALK receptors, could also protect neurons against OGD and this effect was abolished in a7nAChR knockout mice, suggesting cross-talk between these two pathways. Our experiments reveal that STI1 activates multiple signaling pathways that cooperate to increase neuronal resilience in neurons subjected to ischemic insult.
Materials and methods

Materials
Recombinant mouse STI1 (His 6 -STI1) was generated and purified as described previously (Zanata et al. 2002; Soares et al. 2013; Maciejewski et al. 2016) . Staurosporine (cat#PHZ1271; Invitrogen, Burlington, ON L7L 5Z1 Canada) was used as a positive control to induce apoptotic cell death (Chae et al. 2000) . Methyllycaconitine citrate (MLA; Abcam, Cambridge, UK) was used to inhibit (Bertrand et al. 1997) and PNU 282987 (cat#ab120558; Abcam) to activate a7nAChR signaling (Hajos et al. 2005) . LDN 193189 (cat#6053; Tocris, Burlington, Canada), a small molecule inhibitor of activin A receptor 1 (bone morphogenetic protein type 1 receptors), was used to inhibit ALK2 receptors (Cuny et al. 2008) . BMP4 (cat#SRP3298; SigmaAldrich, Oakville, Ontario, Canada) dissolved in 10 mM citric acid was used as an agonist for ALK2 receptors (Chaikuad et al. 2012) .
Animals
Hippocampal and cortical neurons were harvested from both male and female mouse embryos at embryonic day 17 and maintained in dishes coated with poly-L-lysine (Sigma-Aldrich) for 7 days (DIV) as described previously Ostapchenko et al. 2013) . The cells were maintained at 37°C and 5% CO 2 in Neurobasal medium (Invitrogen) supplied with 19 penicillin/ streptomycin mix (Invitrogen), 2 mM L-glutamine (Invitrogen), and 19 B27 supplement (Invitrogen). Half of the medium was replaced every 2-3 days. Prnp 0/0 mice in a C57BL/6 background were kindly donated by Dr. Frank Jirik, University of Calgary , and were maintained in our facility. Briefly, Prnp 0/0 mice (RRID:MGI:2174709, Zurich I strain; Bueler et al. 1992) were backcrossed for several generations (N = 7-8) into C57BL/6 mice (Khosravani et al. 2008; Tsutsui et al. 2008 (Nicholls et al. 2017 ) was used to identify live neurons undergoing apoptosis. This transgenic reporter line takes advantage of the bimolecular fluorescence complementation technique (Hu et al. 2002) instead of more laborious FRET imaging to generate fluorescence in response to caspase 3 activity. Namely, the fluorophore monomeric-Cerulean (Rizzo et al. 2004 ) is split into two pieces; neither piece is fluorescent on its own, but together the fragments reconstitute the fully functional fluorescent protein. The N-and C-terminal portions of Cerulean are targeted to separate subcellular compartments. In addition, both fragments contain a PEST protein degradation sequence, which shortens protein half-life to approximately 1 h. Nuclear export and nuclear localization signals and PEST sequences are linked to the N-and C-Cerulean portions by DEVDG, caspase 3/7 cleavage sequences, and once caspase 3/7 is activated, the N and C-Cerulean portions are reconstituted with the help of complementary inteins. Apoptosis, therefore, can be quantified by Cerulean fluorescence in cells obtained from these reporter mice. Cultures from a minimum of four individual embryos of both sexes were obtained and analyzed for each OGD experiment. Fluorescence was quantified by using an FV1000 confocal microscope (Olympus, Richmond Hill, Ontario, Canada) equipped with 109/0.3 or 209/0.4 dry objectives. Cerulean fluorescence was detected using excitation at 405 nm and emission at 470-485 nm. Integrated fluorescence was divided by total cell number and normalized to the control cells that were not subjected to OGD using ImageJ software (NIH, Bethesda, MD, USA).
Oxygen-glucose deprivation
Original media were replaced with a glucose-free Neurobasal medium (Invitrogen) with 19 penicillin/streptomycin mix (Invitrogen), 2 mM L-glutamine (Invitrogen), and 19 B27 supplement (Invitrogen). The cells were then placed in an incubator with 0% oxygen for 1 h. Following OGD, the original medium with glucose was restored and the cells were allowed to recover under normal conditions for 3, 12, or 24 h.
Immunofluorescence microscopy
Primary hippocampal neuronal cultures grown on glass coverslips for 7 days were fixed using 2% paraformaldehyde and permeabilized using phosphate-buffered saline (PBS) containing 0.5% Triton X-100 (Sigma-Aldrich). The cells were then blocked using 2% bovine serum albumin in PBS containing 0.1% Triton X-100 (PBS-T) before applying the primary antibodies against NeuN (1 : 200, cat#ab104224, RRID:AB_10711040) and ALK2 (1 : 200, cat#ab60157, RRID:AB_940117, both Abcam). After overnight incubation, the cultures were washed with PBS-T and incubated for 1 h with secondary antibodies, followed by nuclear staining with Hoechst 33342 dye (Invitrogen). Coverslips were mounted using Immu-mount medium (ThermoFisher, Mississauga, Ontario, Canada) and the images were collected using an LSM 510 confocal microscope (Zeiss, Toronto, Ontario, Canada), equipped with a 109/0.3 objective.
Live/dead assay A live/dead mammalian cell viability assay (Invitrogen) was used to determine cell death as described previously Beraldo et al. 2016) . Briefly, the cultures were incubated with the calcein-AM/ethidium homodimer mix according to the manufacturer's instructions in the original medium for 45 min and then washed three times with Krebs-Ringer HEPES buffer. Images were collected from at least six random fields per dish using an LSM 510 confocal microscope (Zeiss), equipped with a 109/0.3 objective, using 488 nm excitation and emission filters 505-525 nm (for calcein) and 650 nm LP (for ethidium homodimer). Cell death levels were quantified as the percentage of dead cells relative to the total number of cells. For all the Live/dead assays the experimenter was blinded during imaging acquisition and quantification. No randomization was performed for assignment of cell culture treatments.
Statistical analysis
The study was not pre-registered. A pre-study power analysis was not conducted, but for all experiments data from at least four independent embryos were obtained, which is the standard in the field. Integrated fluorescence and cell number in cultures were obtained using Measure and Cell Counter instruments in ImageJ software. All data were expressed as the mean AE standard error, and complete datasets were analyzed by one-way ANOVA or two-way ANOVA following by Tukey's post hoc test using GraphPad 5.0 (Prism, La Jolla, CA, USA).
Results
Extracellular STI1 decreases apoptosis and neuronal death induced by OGD Previous experiments indicated that STI1-activated signaling can protect neurons against apoptotic insults, such as treatment with staurosporine (Lopes et al. 2005; Beraldo et al. 2010) or OGD . To investigate the mechanisms by which STI1 protects neurons against OGDinduced cell death, hippocampal neurons obtained from a caspase 3 reporter mouse were submitted to 1-h OGD treatment and reperfusion in the presence or absence of 1 lM STI1. Caspase 3 activity and cell death were measured in the same fields using the fluorescence from the mCerulean protein and ethidium homodimer 1 dye, respectively. Cells were imaged at 3, 12, and 24 h of reperfusion. Increased caspase 3 fluorescence was observed in neurons after 1-h OGD exposure as early as 3 h after treatment (Fig. 1a and b) . Cerulean fluorescence decreased at 12 and 24 h after OGD. Interestingly, treatment of neurons with STI1 significantly decreased caspase-induced fluorescence (Fig. 1b) . Furthermore, cell death in post-OGD cultures pre-treated with STI1 was also significantly lower than in cultures with no STI1 added at all three time points (Fig. 1c) . To test whether STI1 prevents neuronal death in a PrP C -dependent fashion, wild-type and Prnp 0/0 (homozygous for PrP C gene deletion) hippocampal neurons were treated with 1 lM STI1 and submitted to 1-h OGD and 24-h reperfusion. Treatment with STI1 significantly decreased cell death induced by OGD in wild-type neurons ( Fig. 1d and e) . However, STI1 was unable to rescue cell death in Prnp 0/0 cultures ( Fig. 1d and e) .
STI1 engages a7nAChR for neuroprotection
Our previous work suggested that STI1 can engage a complex containing PrP C and a7nAChR in hippocampal neurons for neuronal signaling and neuroprotection against staurosporine-mediated cell death . However, in other neuronal types and cancer cells STI1 can activate signaling independent of PrP C , a7nAChR, or both (Arruda-Carvalho et al. 2007; Tsai et al. 2012; Santos et al. 2013) . To determine the potential role for a7nAChR in STI1-mediated neuroprotection, wild-type hippocampal neurons were treated with various concentrations of the a7nAChR-selective antagonist MLA for 30 min prior to the treatment with 1 lM STI1 and 1-h OGD/24-h reperfusion. MLA treatment inhibited STI1-induced survival of neurons during OGD (Fig. 2a) . To extend these pharmacological experiments, we then used cultured hippocampal neurons obtained from a7nAChR-knockout mice. Hippocampal neurons were treated with 1 lM STI1 followed by 1-h OGD/24-h reperfusion. STI1 neuroprotection against OGD, present in wild-type cultures, was lost in a7nAChR-knockout hippocampal neurons (Fig. 2b) . These results together suggest that STI1 engages PrP C /a7nAChRs to rescue neurons against OGD/reperfusion-induced cell death.
Activation of a7nAChR protects neurons against OGD Previous work suggested that a7nAChRs may provide a new pathway to interfere with outcomes in hemorrhagic stroke (Krafft et al. 2013 ) and activation of nicotinic receptors can protect neurons against OGD (Hejmadi et al. 2003) . To further investigate the potential for activation of a7nAChR to protect neurons against OGD-induced cell death, we used PNU 282987, a selective agonist for a7nAChR. Treatment with variable concentrations of PNU 282987 for 30 min prior to exposure to OGD rescued neuronal death in wild-type mouse hippocampal cultures in a dose-dependent way (Fig. 2c ). Furthermore, we tested whether this effect of PNU 282987 was selective for a7nAChRs. Indeed, similar to STI1, PNU 282987 was unable to prevent OGD-induced neuronal death in a7nAChR-knockout neuronal cultures (Fig. 2d) .
ALK2 receptor inhibition blocks STI1 neuroprotection
Previous experiments have shown that STI1 can also modulate signaling pathways in dorsal root ganglia neurons (Santos et al. 2013) , neurons (Arruda-Carvalho et al. 2007) , and cancer cells (Tsai et al. 2012 ) independently of a7nAChRs. In ovarian cancer, ALK2 activation in response to STI1 induces cell proliferation (Tsai et al. 2012) . To further test whether other signaling pathways can be activated by STI1 we focused on ALK2, a receptor that is still poorly studied in the brain. Expression profile obtained from Allen Mouse Brain Atlas (Lein et al. 2007) indicates selective expression of ALK2 receptors in the hippocampus (http://mouse.brain-map.org/experiment/show/69514714) (Fig. 3a) . Staining of cultured mouse hippocampal neurons for ALK2 showed membrane expression in neurons (Fig. 3b) . To determine the potential involvement of ALK2 in STI1-mediated neuronal protection against OGD, neurons were treated with an ALK2 small molecule inhibitor, LDN 193198, and 1 lM STI1 prior to exposure to OGD. ALK2 inhibition did not increase neuronal death in the absence of STI1, however, the compound prevented STI1 neuroprotection in a dose-dependent manner (Fig. 3c) . To further test the possibility that ALK2 activation can modulate cell death in response to ischemia reperfusion, we used the ALK2 ligand BMP4. Treatment of neurons with BMP4 for 30 min significantly decreased cell death induced by ischemia reperfusion in a dose-dependent way (Fig. 3d) . To test the possibility of cross-talk between ALK2, a7nAChR, and the prion protein, we bypassed STI1 by using BMP4 and PNU 282987 to activate their respective receptors and compared their effects in wild-type, a7nAChR-knockout, and Prnp 0/0 neurons. Surprisingly, when we investigated the effects of BMP4 in the absence of a7nAChRs, we found that the neuroprotection afforded by BMP4 (100 ng/mL) was completely abolished in a7nAChR-knockout neurons (Fig. 3e) , suggesting a role for a7nAChRs in the rescuing effect of BMP4 during OGD. In contrast, in the absence of PrP C both BMP4 and PNU 282987 were still able to prevent OGDinduced neuronal death (Fig. 3f) , suggesting that PrP C is not required to directly modulate these two receptors.
So far, we have shown that STI1 addition prior to OGD activated neuroprotective pathways via a7nAChR and ALK2. However, considering the high demand for pharmacological intervention in post-stroke scenarios, it is important to test whether STI1 can activate neuroprotective pathways and direct prevent neuronal death after the onset of ischemia. For this, we compared treatments of neuronal cultures with STI1, PNU 282987, or BMP4 prior to inducing ischemia and immediately after the OGD treatment. STI1 and PNU 282987 prevented neuronal death only if neurons are treated prior to the OGD exposure, but not when the neurons were exposed to them during reperfusion (Fig. 4a) . Interestingly, BMP4 was equally effective to protect neurons against OGD-induced cell death when it was used either prior to OGD or during the reperfusion period (Figs 3e and 4b) . Of note, prevention of neuronal death by BMP4 was attenuated not only by the ALK2 selective small molecule inhibitor, (n = 4) hippocampal neurons were treated with 1 lM STI1 for 30 min and then subjected to 1 h OGD followed by 24 h reperfusion. (d) Representative images of calcein (LIVE, green) and ethidium homodimer 1 (DEAD, red) fluorescence. (e) Quantification was performed as described in Methods. Results are presented as mean AE SEM; data were analyzed and compared by one-way ANOVA (b and c) or two-way ANOVA (e) and Tukey's post hoc test. ****p < 0.0001, ***p < 0.001 compared to control. Scale bar = 100 lm.
LDN 193189, but also by inhibition of a7nAChRs by MLA (Fig. 4b) . The latter result corroborates the findings in a7nAChR-knockout neurons (Fig. 3e) .
Discussion
Our experiments provide new insights on how extracellular STI1 directly protects neurons against ischemic insults via PrP C and introduces a new therapeutic target in ischemia, the ALK2 receptor. The prion protein functions as a scaffold to regulate multiple signaling pathways involved in neuronal protection and toxicity (Linden et al. 2008; Martins et al. 2010) . In ischemic tissue, expression of the prion protein has been suggested to be neuroprotective (Shyu et al. 2005; Weise et al. 2006 Weise et al. , 2008 . PrP C expression is increased after ischemia in mice, which correlates with the severity of brain lesion (Weise et al. 2004; Mitsios et al. 2007) . Remarkably, STI1 is also up-regulated in ischemic brains from mice and humans (Lee et al. 2013) , and STI1 secretion from astrocytes is increased after OGD treatment Lee et al. 2013) . Reduced levels of STI1 increased strokemediated brain damage, whereas increased STI1 levels in vitro and in vivo protected against ischemia and improved functional recovery Lee et al. 2013) . While STI1-induced migration of peripheral blood stem cells to the site of ischemic injury is an important mechanism for STI1 anti-ischemic action (Lee et al. 2013) , extracellular STI1 can also protect neurons directly against a number of insults that trigger apoptosis Soares et al. 2013) . STI1 induces the endocytosis of PrP C and these two molecules are quickly directed to distinct compartments after internalization (Caetano et al. 2008) . Despite the change in PrP C and STI1 levels in ischemia, increased or decreased STI1 levels do not affect the expression of PrP C (Beraldo et al. 2015) . These data together indicate the potential importance of PrP C /STI1 complex not only in physiological conditions, as previously demonstrated (Lopes et al. 2005; Coitinho et al. 2007 ; Caetano et al. Fig. 2 Effect of activation or inhibition of a7nAChR receptors on stress-inducible phosphoprotein 1 (STI1) neuroprotection against oxygen-glucose deprivation (OGD). (a) Wild-type hippocampal neurons were treated with MLA (2-1000 nm) and/or STI1 (1 lM) for 30 min and then subjected to 1 h OGD. (b) Wild-type hippocampal neurons and a7nAChR-KO neurons were treated with 1 lM STI1 for 30 min and then subjected to 1 h OGD. Wild-type (c) and a7nAChR-KO (d) hippocampal neurons were treated with STI1 (1 lM) and/or PNU 282987 (PNU, 0-20 lM) for 30 min and then subjected to 1 h OGD. Cultures were imaged by confocal microscopy after 24 h of reperfusion and analyzed as described in Methods. Results are presented as mean AE SEM; data were analyzed and compared by one-way ANOVA (a, c and d) or two-way ANOVA (b) and Tukey's post hoc test. ****p < 0.0001, ***p < 0. 001.
2008
; Beraldo et al. 2010 Beraldo et al. , 2013 Martins et al. 2010; Roffe et al. 2010) , but also in response to ischemic insults and other types of cellular stresses. PrP C can interact with several transmembrane receptors to modulate neuronal survival (Beraldo et al. , 2011 or toxicity (You et al. 2012; Um et al. 2013) . Notably, we and others have shown that PrP C interacts directly with mGluR5, a mechanism responsible for the toxicity of amyloid b peptides in Alzheimer's disease (Beraldo et al. 2011 Um et al. 2013) . The PrP C -mGluR5 complex also seems to contribute to alpha-synuclein toxicity (Ferreira et al. 2017) . PrP C can also interact with a7nAChRs to mediate signaling by STI1 . Remarkably, activation of a7nAChRs decreases tissue damage by ischemic and hemorrhagic experimental stroke (Hejmadi et al. 2003; Krafft et al. 2013; Han et al. 2014) .
Our results suggest that neurons are protected against ischemia reperfusion by STI1 at least partially via a7nAChRs. Treatment of neurons with MLA, a specific and competitive a7nAChR antagonist (Bertrand et al. 1997) , abolished the neuroprotective effect of STI1 against OGD. The role of a7nAChR in STI1-mediated neuroprotection against OGD was confirmed in a7nAChR-knockout neurons, for which STI1 showed no protective effect. Moreover, wildtype neurons treated with a7nAChR agonist PNU 282987 had significantly lower OGD-induced cell death, an effect absent in a7nAChR-knockout neurons. In mice, PNU 282987 has been effective in attenuating damages from intracerebral hemorrhage (Hijioka et al. 2012 ) and ischemic stroke (Wang et al. 2017a) . Importantly, previous studies have shown that administration of a7nAChR agonists to humans is well tolerated (Deutsch et al. 2008) . Although we showed here that neuroprotection by STI1 against OGD in neurons is dependent on a7nAChR, activation of these receptors in non-neuronal cells in vivo is also known to have anti-inflammatory effects. Future studies should explore if the suppression of inflammatory cascades plays a role in the STI1-PrP C -a7nAChR mechanism of neuroprotection. STI1 has also been shown to activate cell signaling pathways independent of PrP C . In ovarian cancer cells, secreted STI1 acts as a ligand for the ALK2 receptors leading to cancer cell proliferation (Tsai et al. 2012) . Activins are members of the transforming growth factor b family and transduce their signals through type I and II receptor serine/ threonine kinases (Lotinun et al. 2012; Link et al. 2016) . Activin signaling pathways are involved in cellular proliferation, differentiation, and apoptosis. Interestingly the activin gene is transiently up-regulated in ischemic insults (Mukerji et al. 2007 ) and this up-regulation is associated with the neuroprotective effects of activin pathways in the nervous system (Tretter et al. 2000; Mukerji et al. 2007; Link et al. 2016) . These receptors were previously detected in the hippocampus and we confirmed their cell surface expression in hippocampal neuronal cultures. Interestingly, in agreement with the recent evidence that STI1 can signal via ALK2 in tumor cells, we found that treatment of neurons with LDN 193189 (LDN) , and/or 100 ng/mL BMP4 before or immediately after 1 h OGD followed by reperfusion. Cultures (n = 4) underwent reperfusion for 24 h and were imaged and analyzed as described in Methods. Results are presented as mean AE SEM; data were analyzed and compared by one-way ANOVA (a and b) and Tukey's post hoc test. ****p < 0.0001, **p < 0.01, *p < 0.05 compared to control. was used as a positive control. (d) Wild-type hippocampal neurons were treated with 1 lM STI1 and/or the ALK2 agonist BMP4 (0-500 ng/mL) for 30 min and then subjected to 1 h OGD. (e) Wild-type and a7nAChR-KO hippocampal neurons were treated with 0 or 100 ng/mL BMP4 30 min before (BMP4?OGD) or immediately after being subjected to 1 h OGD (OGD?BMP4). (f) Wild-type and Prnp 0/0 hippocampal neurons were treated with 1 lM STI1, 20 lM PNU 282987 (PNU), or 100 ng/mL BMP4 and then subjected to 1 h OGD. After 24 h reperfusion the cultures (n = 4) were imaged and analyzed as described in Methods.
Results are presented as mean AE SEM; data were analyzed by oneway ANOVA (c and d) or two-way ANOVA (e) and Tukey's post hoc test. ****p < 0.0001, ***p < 0.001.
193189, a specific inhibitor of the intracellular kinase domain of the ALK2 receptor, important for its downstream signaling (Horbelt et al. 2015) , significantly decreased STI1 protection against OGD. Following this observation, we tested whether direct activation of ALK2 receptors protects neurons against OGD. For this, we used BMP4, an established agonist for ALK2 (de Sousa Lopes et al. 2004; Medici et al. 2010) . BMP4 is a family member of bone morphogenetic proteins that are involved in cellular functions such as growth and differentiation (Panchision and McKay 2002) , as well as neuronal apoptosis during early development (Furuta et al. 1997) . Treatment of neurons with BMP4 significantly decreased cell death following OGD, further suggesting that modulation of activin receptors protects against ischemia. Using PrP-null neurons, we established that whereas neuroprotection by STI1 depends on PrP C , both direct activation of ALK2 or a7nAChRs can bypass this PrP C -dependent step. Unexpectedly, neuroprotection against OGD by BMP4 was not observed in neurons from a7nAChR-knockout mice, and neuroprotection was attenuated by MLA, suggesting a functional interaction between ALK2 and a7nAChRs. Future studies should focus on potential mechanisms for this interaction.
Although our experiments provide initial insight on how pre-treatment with STI1 may protect neurons against ischemia, they also show that using STI1 or PNU 282987 during reperfusion is not as effective in providing neuroprotection. Because both STI1 and activation of a7nAChRs have demonstrated to be effective in vivo to prevent ischemic injury, it is possible that such treatments in vivo may elicit additional pathways in non-neuronal cells that are relevant for stroke. For example, STI1 appears to induce the migration of bone marrow-derived stem cells to the sites of injury, which are known to help in improving outcomes in stroke (Lee et al. 2013) . Moreover, a7nAChR activation can also have effects on glia and immune responses, which may also contribute to the improvement observed in vivo (Han et al. 2014) . In contrast, BMP4 could provide direct protection to neurons even after exposure to ischemic insult, suggesting a greater potential for translation beyond biochemical studies. Future experiments should focus on the potential use of BMP4 in models of stroke in vivo.
In summary, our experiments provide new light on the mechanisms by which STI1 can trigger signaling pathways to prevent apoptosis in response to ischemic insult (Fig. 5) . We found that in addition to a7nAChRs, ALK2 receptors also seem to be involved in STI1 neuroprotection, and there is a functional cross-talk between these two pathways. Extracellular STI1 seems to afford neurons with the ability to become more resilient to apoptosis by activating a multiprotein signaling complex organized by PrP C . Fund (M.A.M.P., V.F.P.). The authors declare no competing financial interests. Marco Prado is a handling editor for the Journal of Neurochemistry. All experiments were conducted in compliance with the ARRIVE guidelines.
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